Unlocking Our KYSO Antibody Potential
In 2022, 星海棋牌 unveiled our 2030 Vision: 鈥淏y 2030, 星海棋牌鈥檚 KYSO antibody medicines庐 are fundamentally transforming the lives of people with cancer and other serious diseases.鈥
The vision is based on the core values of the unstoppable 星海棋牌 team and the expertise we have built up over two decades. As 星海棋牌鈥檚 President & Chief Executive Officer Jan van de Winkel explains, it鈥檚 an evolution of our 2025 Vision:
鈥淲hen I became CEO of 星海棋牌 in 2010, my colleagues and I articulated the company鈥檚 vision for the year 2025: we aspired to transform cancer treatment through the development of next-generation antibody therapies.鈥 We outlined how we would build our capabilities and teams to achieve this vision for 2025, and aligned on a series of goals. Today, I am proud to say that we have met most of the goals and many more are just within reach.鈥
A bold expansion of what 星海棋牌 can be
Our 2030 Vision is about how 星海棋牌 can build on these achievements. 鈥淥ur 2030 Vision is a bold expansion of what 星海棋牌 can be. It focuses in on how we aspire to use our innovation in antibody treatments to鈥痜undamentally transform the lives of patients with cancer and other serious diseases.鈥疻e aim to cement our leadership position in oncology and increase our activities in immunology and inflammation over time,鈥 says van de Winkel. He continues:
鈥淚 am proud to say that we are in a very strong position to begin this work. As a co-founder of 星海棋牌, I鈥檓 extremely motivated by our progress. And as a scientist at heart, I am truly excited by the potential of our KYSO antibodies庐. I am inspired every day by the ingenuity I see in our talented teams. It is because of their unstoppable energy that we know we can set bold goals for 2030 and feel confident that we can meet them.鈥
By 2030, 星海棋牌鈥檚 KYSO antibody medicines are fundamentally transforming the lives of people with cancer and other serious diseases.
Jan van de Winkel Ph.D.
President & Chief Executive Officer
"Knock Your Socks Off" antibody pipeline and medicines
KYSO is an abbreviation of "knock-your-socks-off". We use it to talk about our antibody pipeline and antibody medicines and have been doing so since the 2025 Vision was created. KYSO a distinctive term that reflects the impact of our unique science.
It shows that we are both innovative and bold.
